TEVANIAN AVADIS
SEC CIK 1214091 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| DLB | Dolby Laboratories, Inc. | Dir | 3,908 | — | $216.7K | 7 | 2022-02-07 | 2026-02-03 |
Most active insiders at DLB, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | YEAMAN KEVIN J | Pres, CEO, Dir | — | $8.72M |
| 2 | Couling John D | SVP, Entertainment | — | $3.82M |
| 3 | SHERMAN MARK ANDREW | EVP, Gen. Counsel, Sec | — | $1.08M |
| 4 | Revankar Shriram | SVP, Advanced Technology Group | — | $747.9K |
| 5 | Pendleton Todd | SVP, CMO | — | $647.9K |
| 6 | Nicholson Ryan | VP, CAO, Corp. Ctrl | — | $359.5K |
| 7 | Park Robert J | SVP, CFO | — | $277.4K |
| 8 | Prophet Tony A | Dir | — | $223.9K |
| 9 | Rollins Emily | Dir | — | $60.1K |
| 10 | Whitten Marc | Pres, CEO, Dir | — | — |
| 16 | TEVANIAN AVADIS | Dir | — | — |
Transactions 7
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-05 | 2026-02-03 | DLB | Dolby Laboratories, Inc. | TEVANIAN AVADIS | Dir | A - Grant | $0.00 | +3,908 | 3,908 | New | $0 | |
| 2025-02-06 | 2025-02-04 | DLB | Dolby Laboratories, Inc. | TEVANIAN AVADIS | Dir | A - Grant | $0.00 | +3,140 | 3,140 | New | $0 | |
| 2024-02-08 | 2024-02-06 | DLB | Dolby Laboratories, Inc. | TEVANIAN AVADIS | Dir | A - Grant | $0.00 | +2,952 | 2,952 | New | $0 | |
| 2023-02-09 | 2023-02-07 | DLB | Dolby Laboratories, Inc. | TEVANIAN AVADIS | Dir | A - Grant | $0.00 | +3,296 | 3,296 | New | $0 | |
| I | 2023-02-09 | 2023-02-07 | DLB | Dolby Laboratories, Inc. | TEVANIAN AVADIS | Dir | S - Sale | $83.64 | -1,392 | 53.3K | -3% | -$116.4K |
| 2022-02-09 | 2022-02-08 | DLB | Dolby Laboratories, Inc. | TEVANIAN AVADIS | Dir | A - Grant | $0.00 | +2,783 | 2,783 | New | $0 | |
| I | 2022-02-08 | 2022-02-07 | DLB | Dolby Laboratories, Inc. | TEVANIAN AVADIS | Dir | S - Sale | $75.31 | -1,331 | 51.9K | -3% | -$100.2K |
Purchase Sale Sale after option exercise All abbreviations